-
Efficient Androgen Receptor Blockade, Survival Benefit, and Precision Stratification in Clinical Practice
| The 15th Shanghai Urologic Oncology Academic Conference Editor’s Note: The 15th Shanghai Urologic Oncology Academic Conference was held in Pudong, Shanghai, bringing together leading experts in urologic oncology from…
-
China Voice at SABCS | Prof. Liu Yunjiang: ⁶⁸Ga-HER2 PET/CT for Early pCR Prediction in HER2+ Breast Cancer
Editor’s Note: De-escalation and precision tailoring of neoadjuvant therapy have become major trends in the management of HER2-positive early breast cancer, yet accurately predicting pathological response at an early stage…
-
Professor Ma Fei: nab-sirolimus Brings a New Breakthrough for HR+/HER2− Advanced Breast Cancer in the Post-CDK4/6 Inhibitor Era
Editor’s Note: The 48th San Antonio Breast Cancer Symposium (SABCS 2025) recently concluded successfully in San Antonio, USA. At the meeting, Professor Ma Fei and his team from the Cancer…
-
Voices from China at SABCS | Professor Biyun Wang:
ER Loss Requires Vigilance—Evidence Shows Poor Prognosis in Patients with ER Positive-to-Negative Conversion** Editor’s Note:Estrogen receptor (ER)–positive breast cancer has traditionally been regarded as a relatively indolent subtype. However, during…
-
Voices from China at SABCS | Professor Yongmei Yin’s Team Reports Chemotherapy-Free Neoadjuvant RC48 Plus Pyrotinib Regimen Achieving Breakthrough pCR
Editor’s Note: At the 2025 San Antonio Breast Cancer Symposium (SABCS), the team led by Professor Yongmei Yin from the First Affiliated Hospital of Nanjing Medical University / Jiangsu Province…
-
Academician Xu Zhang: Advancing Surgery and Systemic Therapy in Parallel—China’s Comprehensive Management of Urologic Cancers Moves to the Global Forefront
The 9th West China Urologic Oncology Tianfu Academic Conference and the 11th Annual Academic Meeting on Urologic and Male Genitourinary Tumors of the Sichuan Anti-Cancer Association were recently held successfully in Chengdu, Sichuan. Centered on urologic and male genitourinary malignancies, the conference emphasized timeliness and diversity, combining a global perspective with Chinese clinical realities to…
-
Professor Brian Rini: From Transcriptomic Signatures to KIM-1—Breakthroughs in Precision Therapy for Renal Cell Carcinoma | 15th Shanghai Academic Conference on Urologic Oncology
From VEGF-targeted agents to immune-based combinations and novel HIF-2α inhibitors, the expanding therapeutic arsenal for renal cell carcinoma (RCC) has significantly prolonged patient survival. At the same time, it has posed a more demanding challenge for clinicians: how to tailor the optimal treatment for each individual patient and truly achieve precision medicine.
-
Professor Stephen J. Freedland: The EMBARK Study Opens a New Chapter of Intensified Therapy for High-Risk BCR Prostate Cancer
In the treatment pathway of prostate cancer, biochemical recurrence (BCR) represents a critical turning point. Especially for high-risk BCR patients with a short PSA doubling time, how to delay disease progression and improve overall survival (OS) has long been a major clinical concern. At the recent 15th Shanghai Urological Oncology Academic Conference, Oncology Frontier –…
Connecting Medical Expertise through Media